Abstract:
Breast cancer is a significant global health challenge, and polymorphisms in the CYP1B1
gene have been associated with its risk. Given that the effects of genetic polymorphisms on breast
cancer risk vary across populations, region-specific studies are crucial. This study assessed the
associations of four CYP1B1 polymorphisms (rs10012, rs1056827, rs1056836, rs1800440) with
estrogen receptor-positive breast cancer (ER+BC) risk in Kenyan women.
METHODOLOGY
A retrospective hospital-based case-control study involved 64 cases and 19 controls.
Oversampling adjusted the case-control imbalance, increasing the control sample size to 60. DNA
was extracted from buffy coat samples, and target regions were amplified and sequenced via
Sanger sequencing. Sequences were analyzed using Geneious Prime for alignment, quality
trimming, and SNP identification. Statistical analysis was performed using R (R 4.3.3).
RESULTS
The study identified significant associations between CYP1B1 polymorphisms and
ER+BC risk. Specifically, the variant allele C and the codominant model (CC vs. GG) of rs10012,
as well as the variant allele A, dominant (CA - CC vs. AA) and log-additive models of rs1056827,
demonstrated a protective effect with ORs of 0.53 (p = 0.018, 95% CI: 0.31–0.90), 0.28 (p = 0.040,
95% CI: 0.08–0.94), 0.29 (p = 0.001, 95% CI: 0.13–0.63), 0.23 (p = 0.003, 95% CI: 0.08–0.67) and
0.51 (p = 0.005, 95% CI: 0.29–0.91), respectively. In contrast, the recessive (CC vs. GG - GC) and
the log-additive models of rs10012, were linked to an increased risk of ER+BC, with ORs of 2.39
(p = 0.020, 95% CI: 1.14–5.03) and 1.97 (p = 0.014, 95% CI: 1.13–3.44), respectively.
CONCLUSION
These findings reveal the complex interplay between CYP1B1 polymorphisms and
ER+BC risk, with some variants protecting while others increase risk. Further research is
essential to fully understand the effects of these genetic variations on breasts.
